Works matching IS 01676997 AND DT 2014 AND VI 32 AND IP 1

Results: 24

Ring-substituted analogs of 3,3′-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and -independent prostate cancer cells.

Published in:

2014

By:

Goldberg, A.;
Titorenko, V.;
Beach, A.;
Abdelbaqi, K.;
Safe, S.;
Sanderson, J.

Publication type:

Journal Article

Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 68, doi. 10.1007/s10637-013-9987-y

By:

Gu, Mancang;
Yu, Yanke;
Gunaherath, G.;
Gunatilaka, A.;
Li, Dapeng;
Sun, Duxin

Publication type:

Article

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 145, doi. 10.1007/s10637-013-9963-6

By:

Tjulandin, S.;
Moiseyenko, V.;
Semiglazov, V.;
Manikhas, G.;
Learoyd, M.;
Saunders, A.;
Stuart, M.;
Keilholz, U.

Publication type:

Article

Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 14, doi. 10.1007/s10637-013-9971-6

By:

Friedland, Julie;
Smith, Donald;
Sang, Jim;
Acquaviva, Jaime;
He, Suqin;
Zhang, Chaohua;
Proia, David

Publication type:

Article

Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 47, doi. 10.1007/s10637-013-9974-3

By:

Chow, Annabelle;
Wong, Amy;
Francia, Giulio;
Man, Shan;
Kerbel, Robert;
Emmenegger, Urban

Publication type:

Article

Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 188, doi. 10.1007/s10637-013-0054-5

By:

Alva, Ajjai;
Daignault, Stephanie;
Smith, David;
Hussain, Maha

Publication type:

Article

Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 75, doi. 10.1007/s10637-013-9995-y

By:

Li, Zhao;
Zhang, Qian;
Wang, Hai;
Zhang, Ya;
Ding, Ding;
Pan, Li;
Miao, David;
Xu, Shi;
Zhang, Chen;
Luo, Pei;
Naranmandura, Hua;
Chen, Shu

Publication type:

Article

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 113, doi. 10.1007/s10637-013-9956-5

By:

Rubinson, Douglas;
Hochster, Howard;
Ryan, David;
Wolpin, Brian;
McCleary, Nadine;
Abrams, Thomas;
Chan, Jennifer;
Iqbal, Syma;
Lenz, Heinz;
Lim, Dean;
Rose, Jeffrey;
Bekaii-Saab, Tanios;
Chen, Helen;
Fuchs, Charles;
Ng, Kimmie

Publication type:

Article

Ring-substituted analogs of 3,3′-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and -independent prostate cancer cells.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 25, doi. 10.1007/s10637-013-9979-y

By:

Goldberg, A.;
Titorenko, V.;
Beach, A.;
Abdelbaqi, K.;
Safe, S.;
Sanderson, J.

Publication type:

Article

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 104, doi. 10.1007/s10637-013-9953-8

By:

Sunakawa, Yu;
Furuse, Junji;
Okusaka, Takuji;
Ikeda, Masafumi;
Nagashima, Fumio;
Ueno, Hideki;
Mitsunaga, Shuichi;
Hashizume, Kensei;
Ito, Yuichiro;
Sasaki, Yasutsuna

Publication type:

Article

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 135, doi. 10.1007/s10637-013-9952-9

By:

Sharma, Sunil;
Vries, Elisabeth;
Infante, Jeffrey;
Oldenhuis, Corina;
Gietema, Jourik;
Yang, Lin;
Bilic, Sanela;
Parker, Katie;
Goldbrunner, Michael;
Scott, Jeffrey;
Burris, Howard

Publication type:

Article

Antitumor activity of semisynthetic derivatives of Aconitum alkaloids.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 60, doi. 10.1007/s10637-013-9986-z

By:

Chodoeva, Ainura;
Bosc, Jean-Jacques;
Lartigue, Lydia;
Guillon, Jean;
Auzanneau, Céline;
Costet, Pierre;
Zurdinov, Ashiraly;
Jarry, Christian;
Robert, Jacques

Publication type:

Article

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 154, doi. 10.1007/s10637-013-9964-5

By:

Naing, Aung;
Fu, Siqing;
Zinner, Ralph;
Wheler, Jennifer;
Hong, David;
Arakawa, Kazuhito;
Falchook, Gerald;
Kurzrock, Razelle

Publication type:

Article

2-aminothiophene-3-carboxylic acid ester derivatives as novel highly selective cytostatic agents.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 200, doi. 10.1007/s10637-013-9981-4

By:

Balzarini, J.;
Thomas, J.;
Liekens, S.;
Noppen, S.;
Dehaen, W.;
Romagnoli, R.

Publication type:

Article

Acknowledgement of Reviewers 2012.

Published in:: Investigational New Drugs, 2014, v. 32, n. 1, p. 211, doi. 10.1007/s10637-013-0058-1
Publication type:: Article

Rhodamine-marked bombesin: a novel means for prostate cancer fluorescence imaging.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 37, doi. 10.1007/s10637-013-9975-2

By:

Sturzu, Alexander;
Sheikh, Sumbla;
Echner, Hartmut;
Nägele, Thomas;
Deeg, Martin;
Amin, Bushra;
Schwentner, Christian;
Horger, Marius;
Ernemann, Ulrike;
Heckl, Stefan

Publication type:

Article

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 94, doi. 10.1007/s10637-013-9950-y

By:

Raymond, E.;
Alexandre, J.;
Faivre, S.;
Goldwasser, F.;
Besse-Hammer, T.;
Gianella-Borradori, A.;
Jego, V.;
Trandafir, L.;
Rejeb, N.;
Awada, A.

Publication type:

Article

A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 171, doi. 10.1007/s10637-013-0037-6

By:

Jones, Robin;
Ferrari, Stefano;
Blay, Jean;
Navid, Fariba;
Lardelli, Pilar;
Alfaro, Vicente;
Siguero, Mariano;
Soman, Neelesh;
Chawla, Sant

Publication type:

Article

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 195, doi. 10.1007/s10637-013-9980-5

By:

Hoang, Tien;
Campbell, Toby;
Zhang, Chong;
Kim, KyungMann;
Kolesar, Jill;
Oettel, Kurt;
Blank, Jules;
Robinson, Emily;
Ahuja, Harish;
Kirschling, Ron;
Johnson, Peter;
Huie, Michael;
Wims, Mary;
Larson, Martha;
Hernan, Hilary;
Traynor, Anne

Publication type:

Article

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 160, doi. 10.1007/s10637-013-9988-x

By:

LoRusso, Patricia;
Venkatakrishnan, Karthik;
Chiorean, E.;
Noe, Dennis;
Wu, Jing-Tao;
Sankoh, Serap;
Corvez, Maria;
Sausville, Edward

Publication type:

Article

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 178, doi. 10.1007/s10637-013-0045-6

By:

Rosenberg, Jonathan;
Bambury, Richard;
Allen, Eliezer;
Drabkin, Harry;
Lara, Primo;
Harzstark, Andrea;
Wagle, Nikhil;
Figlin, Robert;
Smith, Gregory;
Garraway, Levi;
Choueiri, Toni;
Erlandsson, Fredrik;
Laber, Damian

Publication type:

Article

Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 1, doi. 10.1007/s10637-013-9969-0

By:

Jun, Ah;
Kim, Hyun-Jeong;
Park, Kwang-Kyun;
Son, Kun;
Lee, Dong;
Woo, Mi-Hee;
Chung, Won-Yoon

Publication type:

Article

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 123, doi. 10.1007/s10637-013-9958-3

By:

Eberhardt, Wilfried;
Mitchell, Paul;
Schiller, Joan;
Brown, Michael;
Thomas, Michael;
Mills, Glenn;
Jehl, Valentine;
Urva, Shweta;
Leo, Jeffrey;
Gogov, Sven;
Papadimitrakopoulou, Vassiliki

Publication type:

Article

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 1, p. 87, doi. 10.1007/s10637-013-9949-4

By:

Pant, Shubham;
Burris, Howard;
Moore, Kathleen;
Bendell, Johanna;
Kurkjian, Carla;
Jones, Suzanne;
Moreno, Ofir;
Kuhn, John;
McMeekin, Scott;
Infante, Jeffrey

Publication type:

Article